WP
Wang Philip Li Dirigeant
Other M
HK HK · HKEX
Explore the complete record of transactions filed by Wang Philip Li, Dirigeant. Director active across 1 companies, notably Shanghai Bio-heart Biological Technology Co., Ltd. - B. Cumulatively, 21 disclosures have been recorded. The latest transaction was filed on 15 May 2026 — Purchase. Regulator: HKEX. The full history is free.
Declarations 21 total
€4,392 10,000 shares @ €0.4392 0.0011% mcap 4.4% of flow
HKEX:DA20260515E00041 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) €4,445 10,000 shares @ €0.4445 0.0011% mcap 4.5% of flow
HKEX:DA20260514E00013 · 14 May 2026
Ideal exit: 8 Feb 2027 (T+270) €4,470 10,000 shares @ €0.447 0.0011% mcap 4.5% of flow
HKEX:DA20260513E00437 · 13 May 2026
Ideal exit: 7 Feb 2027 (T+270) €4,720 10,000 shares @ €0.472 0.0012% mcap 4.7% of flow
HKEX:DA20260512E00006 · 12 May 2026
Ideal exit: 6 Feb 2027 (T+270) €4,849 10,000 shares @ €0.4849 0.0012% mcap 4.9% of flow
HKEX:DA20260511E00045 · 11 May 2026
Ideal exit: 5 Feb 2027 (T+270) €4,766 10,000 shares @ €0.4766 0.0012% mcap 4.8% of flow
HKEX:DA20260508E00259 · 8 May 2026
Ideal exit: 2 Feb 2027 (T+270) €4,744 10,000 shares @ €0.4744 0.0012% mcap 4.8% of flow
HKEX:DA20260507E00026 · 7 May 2026
Ideal exit: 1 Feb 2027 (T+270) €4,954 10,000 shares @ €0.4954 0.0012% mcap 5.0% of flow
HKEX:DA20260506E00010 · 6 May 2026
Ideal exit: 31 Jan 2027 (T+270) €5,071 10,000 shares @ €0.5071 0.0013% mcap 5.1% of flow
HKEX:DA20260505E00032 · 30 Apr 2026
Ideal exit: 25 Jan 2027 (T+270) €4,412 10,000 shares @ €0.4412 0.0011% mcap 4.4% of flow
HKEX:DA20260430E00035 · 30 Apr 2026
Ideal exit: 25 Jan 2027 (T+270) €4,542 10,000 shares @ €0.4542 0.0011% mcap 4.6% of flow
HKEX:DA20260429E00037 · 29 Apr 2026
Ideal exit: 24 Jan 2027 (T+270) €4,422 10,000 shares @ €0.4422 0.0011% mcap 4.4% of flow
HKEX:DA20260428E00035 · 28 Apr 2026
Ideal exit: 23 Jan 2027 (T+270) €4,441 10,000 shares @ €0.4441 0.0011% mcap 4.4% of flow
HKEX:DA20260427E00036 · 27 Apr 2026
Ideal exit: 22 Jan 2027 (T+270) €5,007 10,000 shares @ €0.5007 0.0013% mcap 5.0% of flow
HKEX:DA20260423E00019 · 23 Apr 2026
Ideal exit: 18 Jan 2027 (T+270) €5,323 10,000 shares @ €0.5323 0.0013% mcap 5.3% of flow
HKEX:DA20260422E00018 · 22 Apr 2026
Ideal exit: 17 Jan 2027 (T+270) €5,160 10,000 shares @ €0.516 0.0013% mcap 5.2% of flow
HKEX:DA20260421E00033 · 21 Apr 2026
Ideal exit: 16 Jan 2027 (T+270) €5,199 10,000 shares @ €0.5199 0.0013% mcap 5.2% of flow
HKEX:DA20260420E00141 · 20 Apr 2026
Ideal exit: 15 Jan 2027 (T+270) €4,892 10,000 shares @ €0.4892 0.0012% mcap 4.9% of flow
HKEX:DA20260417E00066 · 17 Apr 2026
Ideal exit: 12 Jan 2027 (T+270) €4,640 10,000 shares @ €0.464 0.0012% mcap 4.6% of flow
HKEX:DA20260416E00577 · 14 Apr 2026
Ideal exit: 9 Jan 2027 (T+270) €4,762 10,000 shares @ €0.4762 0.0012% mcap 4.8% of flow
HKEX:DA20260416E00580 · 16 Apr 2026
Ideal exit: 11 Jan 2027 (T+270) €4,606 10,000 shares @ €0.4606 0.0012% mcap 4.6% of flow
HKEX:DA20260416E00579 · 15 Apr 2026
Ideal exit: 10 Jan 2027 (T+270) About Wang Philip Li Philip Li Wang is an executive at Shanghai Bio-heart Biological Technology Co., Ltd. - B -H Sh.